1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-tricyclo(3.3.1.13,7)dec-1-yl-, (1R,3S)- | 778546-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1H-2-Benzopyran-5,6-diol, 1-(aminomethyl)-3,4-dihydro-3-tricyclo(3.3.1.13,7)dec-1-yl-, (1R,3S)-
• 英文别名: (1R,3S)-3-(1-adamantyl)-1-(aminomethyl)-3,4-dihydro-1H-isochromene-5,6-diol
• CAS: 778546-51-3
• 化学式: C₂₀H₂₇NO₃
• 分子量: 329.4
• InChiKey: QLJOSZATCBCBDR-DFKUFRTHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  75.7
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Co-administration of dopamine-receptor binding compounds
  申请人：Fernandes B. Prabhavathi

  公开号：US20070155720A1

  公开（公告）日：2007-07-05

  Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D 1 receptor agonist, and administering to the patient an effective amount of a dopamine D 2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D 1 receptor agonist and a dopamine D 2 receptor antagonist are also described. The D 1 dopamine receptor agonist and the D 2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

  描述了治疗患有神经、精神和精神障碍的患者的方法，包括向患者施用部分和/或全多巴胺D1受体激动剂的有效量，并向患者施用多巴胺D2受体拮抗剂的有效量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以以相同或不同的组合或组合物形式向患者施用。
• Method of Administration of Dopamine Receptor Agonists
  申请人：Fernandes B. Prabhavathi

  公开号：US20070254906A1

  公开（公告）日：2007-11-01

  Methods for treating a patient having pulmonary edema are described. The methods include administering to the lung endobronchial space of the airways of the patient an effective amount of a dopamine D 1 receptor agonist. Dopamine D 1 receptor agonists, including hexahydrobenzophenanthridine, hexahydrothienophenanthridine, phenyltetrahydrobenzazepine, chromenoisoquinoline, naphthoisoquinoline dopamine receptor agonists, and their pharmaceutically acceptable salts, formulated as aerosols and dry powders are also described.

  本文描述了治疗肺水肿患者的方法。该方法包括向患者的呼吸道肺内支气管空间内注射有效量的多巴胺D1受体激动剂。本文还介绍了多巴胺D1受体激动剂，包括六氢苯并苯并芳烃、六氢噻吩并芳烃、苯基四氢苯并氮杂环、香豆素异喹啉、萘异喹啉多巴胺受体激动剂及其药学上可接受的盐，制成气溶胶和干粉。
• Co-Administration of Dopamine-Receptor Binding Compounds
  申请人：Fernandes Prabhavathi B.

  公开号：US20100041690A1

  公开（公告）日：2010-02-18

  Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D 1 receptor agonist, and administering to the patient an effective amount of a dopamine D 2 receptor antagonist, Pharmaceutical compositions comprising a dopamine D 1 receptor agonist and a dopamine D 2 receptor antagonist are also described. The D 1 dopamine receptor agonist and the D 2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

  描述了治疗神经、精神和精神障碍患者的方法，包括向患者施用部分和/或完全的多巴胺D1受体激动剂的有效剂量，并向患者施用多巴胺D2受体拮抗剂的有效剂量。还描述了包含多巴胺D1受体激动剂和多巴胺D2受体拮抗剂的药物组合物。D1多巴胺受体激动剂和D2多巴胺受体拮抗剂可以在同一组合物或不同组合物中向患者施用。
• Fluoro-substituted adamantane derivatives
  申请人：PFIZER INC.

  公开号：EP0870757B1

  公开（公告）日：2002-06-12
• 3- (1' -ADAMANTYL) - 1 - AMINOMETHYL - 3, 4 - DIHYDRO - 5, 6 - DIHYDROXY - 1H - 2 - BENZOPYRAN FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH BETA-AMYLOID INDUCED TOXICITY
  申请人：The University Of Manchester

  公开号：EP2844244A1

  公开（公告）日：2015-03-11